Markets:

Overview

News

Currencies

International

Treasuries

Eisai Ltd ADR (OP:ESALY)

N/A UNCHANGED

Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eisai Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >

Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug ↗

December 20, 2022

Via Benzinga

Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals

December 19, 2022

From Eisai

Via JCN Newswire

The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond ↗

December 18, 2022

These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years.

Via InvestorPlace

Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock ↗

December 18, 2022

Both stocks are heading for double-digit gains this year.

Via The Motley Fool

Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases

December 14, 2022

From Eisai

Via JCN Newswire

Why 2023 Could Be a Big Year for Biogen ↗

December 07, 2022

Investors will soon learn if the company's Alzheimer's treatment gets the green light.

Via The Motley Fool

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

December 01, 2022

From Eisai

Via JCN Newswire

Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies

November 29, 2022

From Eisai

Via JCN Newswire

Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting

November 23, 2022

From Eisai

Via JCN Newswire

Even After This Year’s Melt-Up, Runway Remains for LLY Stock ↗

December 05, 2022

The market hasn't overreacted with its enthusiasm for LLY stock, as the pharma giant makes progress with a blockbuster drug in the making.

Via InvestorPlace

Can These 2 Stocks Crush the Market Again in 2023? ↗

December 04, 2022

Both are riding the wave of major clinical wins

Via The Motley Fool

Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate ↗

November 30, 2022

Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD).

Via Benzinga

Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's ↗

November 30, 2022

Via Benzinga

Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference

November 29, 2022

From Eisai

Via JCN Newswire

Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine

November 29, 2022

From BiogenEisai

Via JCN Newswire

Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success ↗

November 28, 2022

Biogen and Axsome stocks diverged Monday on news out of their Alzheimer's studies.

Via Investor's Business Daily

Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall ↗

November 28, 2022

A 65-year-old woman with early Alzheimer's disease receiving Biogen Inc's (NASDAQ: BIIB) antibody lecanemab treatment to slow the cognitive decline recently died from a massive brain hemorrhage that...

Via Benzinga

2 Stocks Near 52-Week Highs That Could Climb Higher ↗

November 28, 2022

This pair of stocks are bucking the trend and they could climb even higher.

Via The Motley Fool

To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research

November 22, 2022

From Eisai

Via JCN Newswire

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗

November 16, 2022

Neurodegenerative disorders could mean big bucks for some biotechs.

Via Investor's Business Daily

Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage ↗

November 15, 2022

Via Benzinga

Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers ↗

November 14, 2022

Via Benzinga

Why Shares Of Eli Lilly And Biogen Are Rallying Today ↗

November 14, 2022

Shares of Biogen Inc. (NASDAQ: BIIB) and Eli Lilly & Co. (NYSE: LLY) are rallying in premarket trading on Monday despite the negative broader market sentiment.

Via Benzinga

Don't Get Used to Lower Medicare Part B Premiums -- Here's Why ↗

October 29, 2022

Medicare might have to begin paying billions of extra dollars for new drugs in the not-too-distant future.

Via The Motley Fool

Is Biogen a Buy After It Boosted Guidance? ↗

October 26, 2022

There's a much bigger story for this biotech than its improved 2022 outlook.

Via The Motley Fool

Biogen Inches Higher On Third-Quarter Beat, But All Eyes Watch Alzheimer's Drug ↗

October 25, 2022

Biogen's partner, Eisai, will present Phase 3 results for lecanemab next month.

Via Investor's Business Daily

Biogen Q3 Earnings Preview: Key Items For Investors To Watch ↗

October 24, 2022

Biogen Inc (NASDAQ: BIIB) is scheduled to report its third-quarter earnings on Tuesday during the premarket session amid cautious hope for its neurodegenerative disease programs and an ongoing

Via Benzinga

3 Alzheimer's Therapy Stocks to Invest in ↗

October 21, 2022

Alzheimer's treatments could make a big winner of these stocks.

Via The Motley Fool

Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers ↗

October 10, 2022

Via Benzinga

Hey Biogen Investors, Don’t Chase BIIB Stock! ↗

October 05, 2022

If BIIB stock already reflects Biogen's early-stage Alzheimer's disease study results, then the next move could easily be to the downside.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.